WASHINGTON, DC (October 31, 2017) – AAM and our member companies are committed to supporting policies that promote competition and help speed the availability of generic and biosimilar medicines to patients.
AAM is fully committed to compliance with all laws and ethical business practices.
Attribution: Jeff Francer, Senior Vice President and General Counsel
MEDIA CONTACT:
Rachel Schwartz
202.249.7147 (o)
202.251.8881 (c)
Issues